A clinician-facing microbiome report for fibromyalgia

Fibromyalgia affects up to 4% of adults, yet diagnosis remains largely exclusion-based and often delayed. Clinicians rely on symptom reporting and extensive negative testing to rule out inflammatory or autoimmune conditions.

The average time to diagnosis is ~5 years, driving repeated referrals, repeat investigations, and unnecessary cost. The absence of objective biomarkers limits early identification and makes it harder to triage patients into appropriate care pathways. There is a clear need for an accessible, objective tool that supports earlier identification in specialty pain and rheumatology clinics.

SomaBiome is developing a non-invasive clinician-facing report designed to fit existing specialty-clinic workflow. A clinic collects the sample, partner labs perform sequencing, and SomaBiome generates a one-page report for rapid review and triage.

This tool is strictly defined as clinical decision support. It is intended to complement existing clinical assessments; the clinician remains the final decision-maker throughout the diagnostic journey.

SomaBiome is grounded in peer-reviewed fibromyalgia and microbiome research, including foundational fibromyalgia studies and mechanistic work that support clinical translation.

• Fibromyalgia signal (PAIN, 2019): species-level microbiome alterations associated with symptom severity.
• Fibromyalgia bile-acid / microbiome reinforcement (PAIN, 2022): reproducible metabolomic and microbial shifts.
• Mechanistic fibromyalgia evidence (Neuron, 2025): causal evidence linking microbial functions to sensory processing.
• Broader chronic-pain and microbiome studies informing platform robustness: demonstrating reproducible microbiome signatures across independent cohorts and geographies.

Published retrospective research cohorts support the biological signal and classifier development. Prospective clinical validation in real-world workflows remains the key next step.

SomaBiome is deploying a capital-efficient translation strategy centered on specialized pain clinics. By operating as a clinical decision support software layer atop existing sequencing infrastructure, SomaBiome can scale without laboratory ownership.

• Regulatory posture: Positioned as clinical decision support (CDS) under current Canadian frameworks, prioritizing clinician oversight to facilitate faster, safer pilot deployment.
• Operational model: We outsource wet-lab sequencing to accredited partners, keeping our core operations focused on computational analysis and reporting.
• Commercial pathway: Initial prospective pilots in specialty pain clinics in Québec and Israel, focused first on workflow fit, clinical utility, and repeatable lab-to-clinic delivery.

SomaBiome is built for institutional and clinical integration. We focus on partnerships that accelerate the transition from research to real-world clinical utility:

• Clinicians and Specialty Centers: Partners interested in clinical pilots and evaluating objective decision support within specialty pain and rheumatology care pathways.
• Lab / sequencing partners: Accredited partners supporting wet-lab sequencing while SomaBiome focuses on computational analysis and reporting.
• Early Investors / Strategic Partners: Strategic partners looking for research-backed, capital-efficient ventures in clinical decision support.
• Research Collaborators: Investigators seeking to integrate microbiome-based models developed in published research cohorts into translational studies.

Our operational model is dedicated to professional and research environments rather than direct-to-consumer distribution.

If you’re interested in collaborating or learning more, we’d love to connect.